From Wikipedia, the free encyclopedia
Valeant Pharmaceuticals International is a pharmaceutical company with activities spanning the drug discovery pipeline from target identification through clinical trials and commercialization. The focus of the company is on neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of speciality chemical and radiochemical research, development and supply companies with a history stretching back to the 1960's. The company has undergone major management, operational and strategic restructurings since the 1990's when shareholders of several group units approved the merger of ICN Pharmaceuticals, ICN Biomedicals, SPI Pharmaceuticals and Viratek into a new global entity, ICN Pharmaceuticals, the immediate forebear of Valeant.
